Vantage Consulting Group Inc Biogen Inc. Transaction History
Vantage Consulting Group Inc
- $68.1 Million
- Q1 2024
A detailed history of Vantage Consulting Group Inc transactions in Biogen Inc. stock. As of the latest transaction made, Vantage Consulting Group Inc holds 1,065 shares of BIIB stock, worth $245,013. This represents 0.34% of its overall portfolio holdings.
Number of Shares
1,065
Previous 979
8.78%
Holding current value
$245,013
Previous $253,000
9.49%
% of portfolio
0.34%
Previous 0.39%
Shares
14 transactions
Others Institutions Holding BIIB
# of Institutions
1,046Shares Held
126MCall Options Held
1.37MPut Options Held
1.35M-
Vanguard Group Inc Valley Forge, PA16.6MShares$3.81 Billion0.07% of portfolio
-
Primecap Management CO Pasadena, CA16.2MShares$3.73 Billion2.65% of portfolio
-
Black Rock Inc. New York, NY14.1MShares$3.25 Billion0.07% of portfolio
-
State Street Corp Boston, MA6.75MShares$1.55 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.17MShares$1.19 Billion0.68% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $33.1B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...